The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 12, pp. 1825-1830. DOI 10.1345/aph.1D262
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D

OBJECTIF: Discuter de la pharmacologie, de la pharmacocinétique, et de la place du bortezomib dans le traitement du myélome multiple.

REVUE DE LITTÉRATURE: Une recherche MEDLINE (janvier 1985 à mai 2003) a été effectuée. Des résumés de congrès scientifiques ainsi que des bibliographies d'articles ont également été utilisés pour les fins de cet article. Toutes les données publiées traitant de l'utilisation du bortezomib dans le traitement du myélome multiple ont été considérées. Toutes les études cliniques, particulièrement celles de Phase II, ont été retenues.

RÉSUMÉ: Les traitements actuellement disponibles pour le myélome multiple permettent l'obtention de résultats significatifs mais temporaires. Le bortezomib est un nouvel anti-cancéreux ayant une activité significative dans les cas de myélome multiple en rechute et réfractaires.

CONCLUSIONS: La recherche clinique sur le bortezomib est peu avancée. Toutefois, il représente une nouvelle modalité de traitement pour les patients souffrant d'un myélome multiple et chez qui peu d'alternatives thérapeutiques sont disponibles.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. A. Luster, J. A. Carrell, K. McCormick, D. Sun, and R. Humphreys
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib
Mol. Cancer Ther., February 1, 2009; 8(2): 292 - 302.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. A. Poff, C. T. Allen, B. Traughber, A. Colunga, J. Xie, Z. Chen, B. J. Wood, C. Van Waes, K. C. P. Li, and V. Frenkel
Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib
Radiology, August 1, 2008; 248(2): 485 - 491.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. M. Bailey, D. E. Abbott, N. V. Margaryan, Z. Khalkhali-Ellis, and M. J. C. Hendrix
Interferon Regulatory Factor 6 Promotes Cell Cycle Arrest and Is Regulated by the Proteasome in a Cell Cycle-Dependent Manner
Mol. Cell. Biol., April 1, 2008; 28(7): 2235 - 2243.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Attar, D. J. DeAngelo, J. G. Supko, F. D'Amato, D. Zahrieh, A. Sirulnik, M. Wadleigh, K. K. Ballen, S. McAfee, K. B. Miller, et al.
Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Clin. Cancer Res., March 1, 2008; 14(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma
Blood, February 1, 2008; 111(3): 1309 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Koschny, H. Holland, J. Sykora, T. L. Haas, M. R. Sprick, T. M. Ganten, W. Krupp, M. Bauer, P. Ahnert, J. Meixensberger, et al.
Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis
Clin. Cancer Res., June 1, 2007; 13(11): 3403 - 3412.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. R. Chade, J. Herrmann, X. Zhu, J. D. Krier, A. Lerman, and L. O. Lerman
Effects of Proteasome Inhibition on the Kidney in Experimental Hypercholesterolemia
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1005 - 1012.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stanford, B. L
Right arrow Articles by Zondor, S. D

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.